WO2011017690A3 - Administration intracellulaire d'agents de contraste avec des nanoparticules fonctionnalisées - Google Patents

Administration intracellulaire d'agents de contraste avec des nanoparticules fonctionnalisées Download PDF

Info

Publication number
WO2011017690A3
WO2011017690A3 PCT/US2010/044844 US2010044844W WO2011017690A3 WO 2011017690 A3 WO2011017690 A3 WO 2011017690A3 US 2010044844 W US2010044844 W US 2010044844W WO 2011017690 A3 WO2011017690 A3 WO 2011017690A3
Authority
WO
WIPO (PCT)
Prior art keywords
intracellular delivery
contrast agents
functionalized nanoparticles
functionalized
nanoparticles
Prior art date
Application number
PCT/US2010/044844
Other languages
English (en)
Other versions
WO2011017690A2 (fr
Inventor
Chad A. Mirkin
Thomas J. Meade
Ying Song
Xiaoyang Xu
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Priority to US13/388,629 priority Critical patent/US20120269730A1/en
Publication of WO2011017690A2 publication Critical patent/WO2011017690A2/fr
Publication of WO2011017690A3 publication Critical patent/WO2011017690A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
    • A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions et des procédés pour l'administration intracellulaire d'un agent de contraste avec une nanoparticule fonctionnalisée.
PCT/US2010/044844 2009-08-07 2010-08-09 Administration intracellulaire d'agents de contraste avec des nanoparticules fonctionnalisées WO2011017690A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/388,629 US20120269730A1 (en) 2009-08-07 2010-08-09 Intracellular Delivery of Contrast Agents with Functionalized Nanoparticles

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23230009P 2009-08-07 2009-08-07
US61/232,300 2009-08-07
US23913309P 2009-09-02 2009-09-02
US61/239,133 2009-09-02

Publications (2)

Publication Number Publication Date
WO2011017690A2 WO2011017690A2 (fr) 2011-02-10
WO2011017690A3 true WO2011017690A3 (fr) 2011-06-16

Family

ID=43544975

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/044844 WO2011017690A2 (fr) 2009-08-07 2010-08-09 Administration intracellulaire d'agents de contraste avec des nanoparticules fonctionnalisées

Country Status (2)

Country Link
US (1) US20120269730A1 (fr)
WO (1) WO2011017690A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138145A1 (fr) 2005-06-14 2006-12-28 Northwestern University Nanoparticules fonctionnalisees d'acide nucleique pour applications therapeutiques
CN103966345A (zh) 2007-02-09 2014-08-06 西北大学 检测细胞内标靶的颗粒
EP2365803B1 (fr) 2008-11-24 2017-11-01 Northwestern University Compositions de nanoparticules d arn polyvalentes
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CN102666879B (zh) 2009-10-30 2016-02-24 西北大学 模板化的纳米缀合物
WO2011091065A2 (fr) 2010-01-19 2011-07-28 Northwestern University Nanostructures synthétiques comprenant des acides nucléiques et/ou d'autres entités
CA2796435C (fr) * 2010-04-15 2019-05-07 The Washington University Compositions de promedicament, nanoparticules de promedicament, et procedes d'utilisation de celles-ci
WO2013036974A1 (fr) 2011-09-11 2013-03-14 Aurasense, Llc Systèmes de commande de capture cellulaire
ES2856091T3 (es) 2011-09-14 2021-09-27 Univ Northwestern Nanoconjugados capaces de atravesar la barrera hematoencefálica
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
EP3024494A1 (fr) 2013-07-25 2016-06-01 Exicure, Inc. Constructions à base d'acides nucléiques sphériques utilisées en tant qu'agents d'immunorégulation
EP3024936B1 (fr) 2013-07-25 2019-09-04 Exicure, Inc. Constructions à partir d'acides nucléiques sphériques utilisées en tant qu'agents immunostimulants à des fins prophylactiques et thérapeutiques
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
WO2015187966A1 (fr) 2014-06-04 2015-12-10 Aurasense Therapeutics, Llc Libération polyvalente de modulateurs immunitaires par des acides nucléiques sphériques liposomaux pour des applications prophylactiques ou thérapeutiques
SG11201702656WA (en) 2014-10-06 2017-04-27 Exicure Inc Anti-tnf compounds
WO2016081911A2 (fr) 2014-11-21 2016-05-26 Northwestern University Absorption cellulaire spécifique à une séquence de conjugués nanoparticulaires d'acides nucléiques sphériques
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
CA3023451A1 (fr) 2016-05-06 2017-11-09 Exicure, Inc. Constructions d'acides nucleiques spheriques liposomales (sna) presentant des oligonucleotides antisens (aso) pour l'inactivation specifique de l'arnm du recepteur de l'interleukine 17
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018201090A1 (fr) 2017-04-28 2018-11-01 Exicure, Inc. Synthèse d'acides nucléiques sphériques à l'aide de fractions lipophiles
US11162192B2 (en) 2017-12-01 2021-11-02 Arizona Board Of Regents On Behalf Of Arizona State University Materials and methods relating to single molecule arrays
EP3752205A2 (fr) 2018-02-14 2020-12-23 Boston Scientific Scimed Inc. Agents de contraste à base de gadolinium, procédés d'élimination et système d'élimination
US11717202B2 (en) 2019-04-10 2023-08-08 Foothold Labs Inc. Mobile lab-on-a-chip diagnostic system

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006064451A2 (fr) * 2004-12-17 2006-06-22 Koninklijke Philips Electronics N.V. Agents de contraste de ciblage ou agents therapeutiques de ciblage destines a une imagerie et a une therapie moleculaires
WO2006064453A2 (fr) * 2004-12-17 2006-06-22 Koninklijke Philips Electronics N.V. Agents de ciblage pour une imagerie moleculaire
US20080213177A1 (en) * 2004-05-24 2008-09-04 Thomas William Rademacher Nanoparticles Comprising Rna Ligands
US20090155173A1 (en) * 2005-10-28 2009-06-18 Centre National De La Recherche Scientifique (Cnrs) Persistent luminescence nanoparticles used in the form of a diagnosis agent for in vivo optical imaging

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020004593A1 (en) * 1998-11-13 2002-01-10 Thomas J. Meade Methods of making modified nucleosides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213177A1 (en) * 2004-05-24 2008-09-04 Thomas William Rademacher Nanoparticles Comprising Rna Ligands
WO2006064451A2 (fr) * 2004-12-17 2006-06-22 Koninklijke Philips Electronics N.V. Agents de contraste de ciblage ou agents therapeutiques de ciblage destines a une imagerie et a une therapie moleculaires
WO2006064453A2 (fr) * 2004-12-17 2006-06-22 Koninklijke Philips Electronics N.V. Agents de ciblage pour une imagerie moleculaire
US20090155173A1 (en) * 2005-10-28 2009-06-18 Centre National De La Recherche Scientifique (Cnrs) Persistent luminescence nanoparticles used in the form of a diagnosis agent for in vivo optical imaging

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALRIC, C. ET AL.: "Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging.", J AM CHEM SOC., vol. 130, no. 18, 7 May 2008 (2008-05-07), pages 5908 - 5915, XP002500093, DOI: doi:10.1021/ja078176p *
AMIRKHANOV, N. V. ET AL.: "Design of (Gd-D03A)n-polydiamidopropanoyl-peptide nucleic acid-D(Cys-Ser-Lys-Cys) magnetic resonance contrast agents.", BIOPOLYMERS., vol. 89, no. 12, 2008, pages 1061 - 1076, XP055083652, DOI: doi:10.1002/bip.21059 *
ENDRES, P.J. ET AL.: "DNA-Ti02 nanoconjugates labeled with magnetic resonance contrast agents.", J AM CHEM SOC., vol. 129, no. 51, 26 December 2007 (2007-12-26), pages 15760 - 15761 *
PARK, J. A. ET AL.: "Gold nanoparticles functionalised by Gd-complex of DTPA-bis(amide) conjugate of glutathione as an MRI contrast agent.", BIOORG MED CHEM LETT., vol. 18, no. 23, 1 December 2008 (2008-12-01), pages 6135 - 6137, XP025646291, DOI: doi:10.1016/j.bmcl.2008.10.017 *
PAUNESKU, T. ET AL.: "Gadolinium-conjugated Ti02-DNA oligonucleotide nanoconjugates show prolonged intracellular retention period and Tl-weighted contrast enhancement in magnetic resonance images.", NANOMEDICINE., vol. 4, no. 3, 2008, pages 201 - 207 *
THURN, K.T. ET AL.: "Labeling Ti02 nanoparticles with dyes for optical fluorescence microscopy and determination of Ti02-DNA nanoconjugate stability.", SMALL., vol. 5, no. 11, June 2009 (2009-06-01), pages 1318 - 1325 *

Also Published As

Publication number Publication date
WO2011017690A2 (fr) 2011-02-10
US20120269730A1 (en) 2012-10-25

Similar Documents

Publication Publication Date Title
WO2011017690A3 (fr) Administration intracellulaire d'agents de contraste avec des nanoparticules fonctionnalisées
IL272313A (en) Intravascular delivery of nanoparticle preparations and their uses
WO2011017456A3 (fr) Délivrance localisée de nanoparticules pour applications thérapeutiques et diagnostiques
IL208260A0 (en) Nanoparticles for targeted delivery of active agents to the lung
WO2012061607A3 (fr) Compositions comprenant des nanostructures fonctionnalisées à base de carbone et procédés associés
EP2670549A4 (fr) Nanoparticules en métal lourd à surface modifiée, compositions et utilisations associées
EP2558072A4 (fr) Compositions de promédicament, nanoparticules de promédicament, et procédés d'utilisation de celles-ci
EP2515956B8 (fr) Composition comportant des nanoparticules de tio2
IL221886A (en) Composition containing nanomaterials containing Texan and albumin, combinations of the preparation with additional factors and their uses
WO2011081430A3 (fr) Composition de formulation pour injection de nanoparticules polymères, contenant de la rapamycine et présentant une solubilité dans l'eau améliorée, son procédé de préparation, et composition anticancéreuse pour utilisation en combinaison avec une radiothérapie
IL215765A0 (en) Prion-free nanoparticle compositions and methods
EP2391579A4 (fr) Compositions de nanoparticules à surface modifiée
EP2162386A4 (fr) Procédé de formation de nanoparticules fonctionnalisées stables
IL227625A0 (en) Nanoparticle compounds, their formulations, and their use
EP2012751A4 (fr) Nouvelles nanoparticules destinees a la delivrance d'agents actifs
WO2011131943A8 (fr) Compositions pharmaceutiques
EP2349237A4 (fr) Nanoparticules de curcumine et leurs procédés de production
EP2419535A4 (fr) Administration de nanoparticules fonctionnalisée par des oligonucléotides
IL226377B (en) Preparations of isoflavone nanoparticles and methods for their preparation and use
EP2337818A4 (fr) Compositions aqueuses de polyuréthane-urée comprenant des dispersions et des films
WO2012040331A3 (fr) Nanoparticules multicouches
WO2011160060A3 (fr) Agent de fixation de sélénium
EP2501646A4 (fr) Compositions pigmentaires inorganiques comprenant des nanoparticules modifiées en surface et leurs procédés de fabrication
PT2376060E (pt) Composições de nanopartículas
MX366744B (es) Composición super-hidrofóbica, su preparación y papel que presenta super-hidrofobicidad.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10807282

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13388629

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 10807282

Country of ref document: EP

Kind code of ref document: A2